Orion Oyj/ FI0009014377 /
| 8/21/2024 4:09:03 PM | Chg. - | Volume | Bid8/12/2024 | Ask8/2/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 46.67EUR | - | 85 Turnover: 3,970.20 |
-Bid Size: - | -Ask Size: - | 5.17 bill.EUR | 3.35% | 31.37 |
GlobeNewswire
7/17
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation...
GlobeNewswire
7/1
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive ...
GlobeNewswire
6/3
Orion is developing the Finnish life science industry in a unique collaboration project
GlobeNewswire
1/8
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ...
GlobeNewswire
1/5
Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patient...
GlobeNewswire
12/27/2023
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
GlobeNewswire
3/24/2022
Orion is planning to refocus its R&D – in the future focus would be on cancer and pain
GlobeNewswire
2/18/2022
Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU
GlobeNewswire
2/17/2022
Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall surviva...
GlobeNewswire
12/3/2021
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets...
GlobeNewswire
6/9/2021
Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality...
GlobeNewswire
12/9/2019
Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND
GlobeNewswire
7/31/2019
U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant pro...
GlobeNewswire
5/31/2019
2019 American Society of Clinical Oncology (ASCO) Annual Meeting - Darolutamide data presented
